Amneal Pharmaceuticals AMRX
NASDAQ AMRX
$21.24 -0.14 (-0.65%)
As of: Nov 16, 2026 · 9:55 AM EST

Amneal Pharmaceuticals (AMRX) Cash from Restructuring (2018 - 2021)

Updated

Amneal Pharmaceuticals (AMRX) recorded Cash from Restructuring of -$788,000 in Q4 2021, compared with -$3.19 million a year earlier.

Analysis

Amneal Pharmaceuticals (AMRX) Cash from Restructuring (2018 - 2021) Analysis & Trends

On a TTM basis, Amneal Pharmaceuticals' Cash from Restructuring came in at -$3.28 million as of Dec 31, 2021; for FY2020, it was -$536,000.

  • Across earlier years, Cash from Restructuring came in at $12.46 million in FY2019 (+10.3%) and $11.3 million in FY2018.
  • Quarterly Cash from Restructuring has ranged from -$17.47 million in Q4 2019 to $20.94 million in Q3 2019 over the past five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,304.70 Bn 1,278.32 Bn 20.46 Bn
2 Johnson & Johnson 690.68 Bn 610.54 Bn 17.30 Bn
3 AbbVie 528.28 Bn 496.29 Bn 13.12 Bn
4 Merck 365.24 Bn 328.18 Bn 13.19 Bn
5 Novartis Ag 314.66 Bn 287.90 Bn -
6 Astrazeneca 288.53 Bn 262.05 Bn 13.26 Bn
7 Amgen 253.39 Bn 205.04 Bn 7.58 Bn
8 Gilead Sciences 210.48 Bn 185.59 Bn 6.73 Bn
9 Pfizer 165.27 Bn 112.63 Bn 12.56 Bn
10 Amneal Pharmaceuticals 7.17 Bn 6.41 Bn 334.12 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 -788,000.00
Sep 30, 2021 425,000.00
Dec 31, 2020 -3.19 Mn
Sep 30, 2020 276,000.00
Jun 30, 2020 333,000.00
Dec 31, 2019 -17.47 Mn
Sep 30, 2019 20.94 Mn
Jun 30, 2019 2.84 Mn
Dec 31, 2018 11.30 Mn
API Access

Amneal Pharmaceuticals Cash from Restructuring API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-restructuring&ticker=AMRX&period=max&api_key=YOUR_API_KEY